Engagement of the OX-40 receptor in vivo enhances antitumor immunity

Andrew D. Weinberg, Martin Muy Rivera, Rodney Prell, Arden Morris, Trygg Ramstad, John Vetto, Walter J. Urba, Gregory Alvord, Campbell Bunce, John Shields

    Research output: Contribution to journalArticle

    273 Citations (Scopus)

    Abstract

    The OX-40 receptor (OX-40R), a member of the TNFR family, is primarily expressed on activated CD4+ T lymphocytes. Engagement of the OX-40R, with either OX-40 ligand (OX-40L) or an Ab agonist, delivers a strong costimulatory signal to effector T cells. OX-40R+ T cells isolated from inflammatory lesions in the CNS of animals with experimental autoimmune encephalomyelitis are the cells that respond to autoantigen (myelin basic protein) in vivo. We identified OX-40R+ T cells within primary tumors and tumor-invaded lymph nodes of patients with cancer and hypothesized that they are the tumor-Ag-specific T cells. Therefore, we investigated whether engagement of the OX-40R in vivo during tumor priming would enhance a tumor- specific T cell response. Injection of OX-40L:Ig or anti-OX-40R in vivo during tumor priming resulted in a significant improvement in the percentage of tumor-free survivors (20-55%) in four different murine tumors derived from four separate tissues. This anti-OX-40R effect was dose dependent and accentuated tumor-specific T cell memory. The data suggest that engagement of the OX-40R in vivo augments tumor-specific priming by stimulating/expanding the natural repertoire of the host's tumor-specific CD4+ T cells. The identification of OX-40R+ T cells clustered around human tumor cells in vivo suggests that engagement of the OX-40R may be a practical approach for expanding tumor-reactive T cells and thereby a method to improve tumor immunotherapy in patients with cancer.

    Original languageEnglish (US)
    Pages (from-to)2160-2169
    Number of pages10
    JournalJournal of Immunology
    Volume164
    Issue number4
    StatePublished - Feb 15 2000

    Fingerprint

    Immunity
    Neoplasms
    T-Lymphocytes
    T-Cell Antigen Receptor
    Ligands
    Myelin Basic Protein
    Autoimmune Experimental Encephalomyelitis
    Immunotherapy
    Survivors
    Lymph Nodes

    ASJC Scopus subject areas

    • Immunology

    Cite this

    Weinberg, A. D., Rivera, M. M., Prell, R., Morris, A., Ramstad, T., Vetto, J., ... Shields, J. (2000). Engagement of the OX-40 receptor in vivo enhances antitumor immunity. Journal of Immunology, 164(4), 2160-2169.

    Engagement of the OX-40 receptor in vivo enhances antitumor immunity. / Weinberg, Andrew D.; Rivera, Martin Muy; Prell, Rodney; Morris, Arden; Ramstad, Trygg; Vetto, John; Urba, Walter J.; Alvord, Gregory; Bunce, Campbell; Shields, John.

    In: Journal of Immunology, Vol. 164, No. 4, 15.02.2000, p. 2160-2169.

    Research output: Contribution to journalArticle

    Weinberg, AD, Rivera, MM, Prell, R, Morris, A, Ramstad, T, Vetto, J, Urba, WJ, Alvord, G, Bunce, C & Shields, J 2000, 'Engagement of the OX-40 receptor in vivo enhances antitumor immunity', Journal of Immunology, vol. 164, no. 4, pp. 2160-2169.
    Weinberg AD, Rivera MM, Prell R, Morris A, Ramstad T, Vetto J et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. Journal of Immunology. 2000 Feb 15;164(4):2160-2169.
    Weinberg, Andrew D. ; Rivera, Martin Muy ; Prell, Rodney ; Morris, Arden ; Ramstad, Trygg ; Vetto, John ; Urba, Walter J. ; Alvord, Gregory ; Bunce, Campbell ; Shields, John. / Engagement of the OX-40 receptor in vivo enhances antitumor immunity. In: Journal of Immunology. 2000 ; Vol. 164, No. 4. pp. 2160-2169.
    @article{906d36a549aa497b99407ca1a973100e,
    title = "Engagement of the OX-40 receptor in vivo enhances antitumor immunity",
    abstract = "The OX-40 receptor (OX-40R), a member of the TNFR family, is primarily expressed on activated CD4+ T lymphocytes. Engagement of the OX-40R, with either OX-40 ligand (OX-40L) or an Ab agonist, delivers a strong costimulatory signal to effector T cells. OX-40R+ T cells isolated from inflammatory lesions in the CNS of animals with experimental autoimmune encephalomyelitis are the cells that respond to autoantigen (myelin basic protein) in vivo. We identified OX-40R+ T cells within primary tumors and tumor-invaded lymph nodes of patients with cancer and hypothesized that they are the tumor-Ag-specific T cells. Therefore, we investigated whether engagement of the OX-40R in vivo during tumor priming would enhance a tumor- specific T cell response. Injection of OX-40L:Ig or anti-OX-40R in vivo during tumor priming resulted in a significant improvement in the percentage of tumor-free survivors (20-55{\%}) in four different murine tumors derived from four separate tissues. This anti-OX-40R effect was dose dependent and accentuated tumor-specific T cell memory. The data suggest that engagement of the OX-40R in vivo augments tumor-specific priming by stimulating/expanding the natural repertoire of the host's tumor-specific CD4+ T cells. The identification of OX-40R+ T cells clustered around human tumor cells in vivo suggests that engagement of the OX-40R may be a practical approach for expanding tumor-reactive T cells and thereby a method to improve tumor immunotherapy in patients with cancer.",
    author = "Weinberg, {Andrew D.} and Rivera, {Martin Muy} and Rodney Prell and Arden Morris and Trygg Ramstad and John Vetto and Urba, {Walter J.} and Gregory Alvord and Campbell Bunce and John Shields",
    year = "2000",
    month = "2",
    day = "15",
    language = "English (US)",
    volume = "164",
    pages = "2160--2169",
    journal = "Journal of Immunology",
    issn = "0022-1767",
    publisher = "American Association of Immunologists",
    number = "4",

    }

    TY - JOUR

    T1 - Engagement of the OX-40 receptor in vivo enhances antitumor immunity

    AU - Weinberg, Andrew D.

    AU - Rivera, Martin Muy

    AU - Prell, Rodney

    AU - Morris, Arden

    AU - Ramstad, Trygg

    AU - Vetto, John

    AU - Urba, Walter J.

    AU - Alvord, Gregory

    AU - Bunce, Campbell

    AU - Shields, John

    PY - 2000/2/15

    Y1 - 2000/2/15

    N2 - The OX-40 receptor (OX-40R), a member of the TNFR family, is primarily expressed on activated CD4+ T lymphocytes. Engagement of the OX-40R, with either OX-40 ligand (OX-40L) or an Ab agonist, delivers a strong costimulatory signal to effector T cells. OX-40R+ T cells isolated from inflammatory lesions in the CNS of animals with experimental autoimmune encephalomyelitis are the cells that respond to autoantigen (myelin basic protein) in vivo. We identified OX-40R+ T cells within primary tumors and tumor-invaded lymph nodes of patients with cancer and hypothesized that they are the tumor-Ag-specific T cells. Therefore, we investigated whether engagement of the OX-40R in vivo during tumor priming would enhance a tumor- specific T cell response. Injection of OX-40L:Ig or anti-OX-40R in vivo during tumor priming resulted in a significant improvement in the percentage of tumor-free survivors (20-55%) in four different murine tumors derived from four separate tissues. This anti-OX-40R effect was dose dependent and accentuated tumor-specific T cell memory. The data suggest that engagement of the OX-40R in vivo augments tumor-specific priming by stimulating/expanding the natural repertoire of the host's tumor-specific CD4+ T cells. The identification of OX-40R+ T cells clustered around human tumor cells in vivo suggests that engagement of the OX-40R may be a practical approach for expanding tumor-reactive T cells and thereby a method to improve tumor immunotherapy in patients with cancer.

    AB - The OX-40 receptor (OX-40R), a member of the TNFR family, is primarily expressed on activated CD4+ T lymphocytes. Engagement of the OX-40R, with either OX-40 ligand (OX-40L) or an Ab agonist, delivers a strong costimulatory signal to effector T cells. OX-40R+ T cells isolated from inflammatory lesions in the CNS of animals with experimental autoimmune encephalomyelitis are the cells that respond to autoantigen (myelin basic protein) in vivo. We identified OX-40R+ T cells within primary tumors and tumor-invaded lymph nodes of patients with cancer and hypothesized that they are the tumor-Ag-specific T cells. Therefore, we investigated whether engagement of the OX-40R in vivo during tumor priming would enhance a tumor- specific T cell response. Injection of OX-40L:Ig or anti-OX-40R in vivo during tumor priming resulted in a significant improvement in the percentage of tumor-free survivors (20-55%) in four different murine tumors derived from four separate tissues. This anti-OX-40R effect was dose dependent and accentuated tumor-specific T cell memory. The data suggest that engagement of the OX-40R in vivo augments tumor-specific priming by stimulating/expanding the natural repertoire of the host's tumor-specific CD4+ T cells. The identification of OX-40R+ T cells clustered around human tumor cells in vivo suggests that engagement of the OX-40R may be a practical approach for expanding tumor-reactive T cells and thereby a method to improve tumor immunotherapy in patients with cancer.

    UR - http://www.scopus.com/inward/record.url?scp=0034651736&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0034651736&partnerID=8YFLogxK

    M3 - Article

    C2 - 10657670

    AN - SCOPUS:0034651736

    VL - 164

    SP - 2160

    EP - 2169

    JO - Journal of Immunology

    JF - Journal of Immunology

    SN - 0022-1767

    IS - 4

    ER -